Clinical trial

SGLT2 Inhibition in Hemodialysis

NCT05179668

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2022-10-01

PhasePHASE2

Study timeline

Study start (actual)2022-10-01Date precision: day

Registry last updated2026-03-03

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Kidney Failureunresolved

Hemodialysisunresolved

Diabetes Mellitus, Type 2unresolved

Chronic Kidney Diseaseunresolved

Left Ventricular Hypertrophyunresolved

Interventions

Dapagliflozin 10 MGDRUG · verified · RxNorm: dapagliflozin 10 MG

Sponsors & collaborators

Medical University of Viennalead sponsor

Mapped research locations

ViennaAustria7 GrazAustria1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05179668 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.